The vaccine will combine an immunogenic spike protein of SARS-CoV-2 expressed by Celonic's Chovolution mammalian cell expression system with Intravacc's Outer Membrane Vesicle (OMV) technology, according to the companies. The firms aim to generate a balanced B- and T-cell response against SARS-CoV-2 with the vaccine.

Celonic said it will construct cell lines producing the spike protein in large quantities and develop a good manufacturing practice production process. The companies expect to begin preclinical studies shortly in order to select the best candidate protein for the vaccine. In addition, the collaboration aims to accelerate the development of Intravacc's COVID-19 OMV protein vaccine, which is expected to enter clinical testing in 2021.

Animal study turns in positive results for Moderna-NIH COVID-19 vaccine
Moderna's COVID-19 vaccine candidate, messenger RNA (mRNA)-1273, has been shown to induce immune responses and control upper and lower respiratory tract...

Soligenix advances COVID-19 vaccine
Biopharmaceutical firm Soligenix said that preclinical immunogenicity studies of its CiVax heat stable subunit COVID-19 vaccine candidate demonstrated...

Moderna begins phase III testing of COVID-19 vaccine
Moderna has begun a phase III clinical trial evaluating its messenger RNA (mRNA)-1273 COVID-19 vaccine candidate. The trial is expected to enroll approximately...

Amyris partners with IDRI on scalable vaccine platform
Amyris and the Infectious Disease Research Institute (IDRI) have inked a binding term sheet for the development of a planned COVID-19 RNA vaccine technology...

Cel-Sci reports positive early results with COVID-19 LEAPS conjugate
Cel-Sci completed animal testing using its Ligand Epitope Antigen Presentation System (LEAPS) COVID-19 conjugate, which means the firm can now move into...